How Biostimulators Differ from HA Fillers
Hyaluronic acid fillers create volume by occupying space: the hydrophilic gel draws water and lifts tissue immediately, and the effect can be reversed with hyaluronidase. Biostimulatory injectables act indirectly. Rather than filling a defect themselves, their particles provoke a controlled fibroblast response, so the visible change depends largely on collagen the patient's own tissue produces over the following weeks.
The shared mechanism is neocollagenesis. Microparticles are recognised as a scaffold, attracting macrophages and fibroblasts and prompting deposition of type I and type III collagen around them. Because this remodelling is gradual, results emerge over weeks to months rather than at the point of injection. The trade-off is that the outcome is less immediately adjustable and cannot be dissolved.
This distinction matters clinically. Neither calcium hydroxylapatite nor poly-L-lactic acid is reversible with hyaluronidase, so conservative placement in the correct plane is essential and vascular events demand a different management pathway from HA. Assessment should weigh skin quality, the volume deficit, and whether a patient understands that the change is progressive rather than instant, before either product is selected.
Calcium Hydroxylapatite: Composition and Dilution
Calcium hydroxylapatite consists of smooth microspheres, roughly 25 to 45 micrometres in diameter, suspended in an aqueous carboxymethylcellulose gel. The gel carrier provides immediate volume on injection, while the microspheres remain to stimulate collagen. As the carrier resorbs over the first two to three months, the biostimulatory contribution becomes the durable component of the result.
Dilution changes what the product does. Injected at or near standard concentration into the deep dermis or supraperiosteal plane, it restores contour and volume. Diluted further with saline and lidocaine — often described as hyperdilution — it is spread as a thinner biostimulatory layer to address skin laxity and quality across regions such as the neck, décolletage, or arms rather than to build structural volume.
Because part of the effect is immediate, patients see contour change at the visit, which then matures as collagen forms. Reported longevity is commonly in the region of twelve to eighteen months, varying with site, dilution, and individual metabolism. The immediate feedback can aid planning, but it can also tempt overcorrection, so restraint at the first session is prudent.
- Use a deep dermal to supraperiosteal plane for contour, and thinner diluted layers for skin quality.
- Calcium hydroxylapatite is not recommended for the lips, where nodules are more frequent.
- The immediate gel volume can mask the eventual collagen-based result, so correct gradually.
- Massage after placement helps distribute the product and reduce palpable irregularity.
- It cannot be dissolved, so conservative volumes and vascular safety take priority.
Poly-L-Lactic Acid: Reconstitution and Gradual Volumisation
Poly-L-lactic acid is a synthetic, biodegradable polymer supplied as a freeze-dried powder of microparticles. It carries no gel carrier, so it must be reconstituted with sterile water before use, frequently with lidocaine added. Once injected, the diluent and any transient swelling settle within days, leaving little immediate volume; the meaningful change is the collagen that develops subsequently.
Reconstitution technique influences both results and safety. Contemporary practice favours generous dilution volumes and allowing the suspension to hydrate, historically for a period before use, with thorough agitation immediately beforehand to disperse particles evenly. Adequate dilution reduces particle clumping, which is associated with the papules and nodules that earlier, more concentrated protocols produced more often.
Treatment is planned as a course, typically two to three sessions spaced around four to six weeks apart, because collagen accrues incrementally. Patients should understand that they are investing in a gradual result and that assessment between sessions guides the endpoint. Longevity is generally longer than HA fillers, with effects often persisting around two years, again subject to individual variation.
Patient Selection and Adverse Events
Patient selection begins with realistic expectations about a progressive result and with a candid assessment of skin quality and volume needs. Both agents suit patients seeking gradual, structural improvement rather than a precisely reversible correction. Relative cautions include a history of keloid or hypertrophic scarring, active local infection, and, particularly for poly-L-lactic acid, a background of autoimmune or inflammatory conditions, which warrants careful consideration.
The most discussed adverse events are papules and nodules. These may be early and technique-related — from superficial placement, overcorrection, or inadequate dispersion — or delayed. Delayed nodules can be inflammatory or, less commonly, represent foreign-body granulomas, an immune-mediated reaction that may appear months later. Differentiating a benign palpable particle collection from an infective or granulomatous nodule guides whether reassurance, massage, intralesional steroid, or antibiotics is appropriate.
Much nodule risk is modifiable. Correct reconstitution and dilution, thorough mixing, placement in the appropriate deep plane, avoidance of high-mobility or thin-skinned areas such as the lips and periorbital region, sensible volumes, and structured post-treatment massage all reduce incidence. These measures are learned skills, and their consistent application is a reasonable marker of a competent injector.
Vascular occlusion, though uncommon, is the most serious concern and is more difficult to manage than with hyaluronic acid because neither product can be dissolved. Sound knowledge of facial vascular anatomy, aspiration where appropriate, slow low-pressure injection, and the use of cannulas in higher-risk regions are therefore central. Every injector should have a clear escalation plan for suspected occlusion.
- Onset weeks to months after treatment rather than immediately.
- Redness, warmth, tenderness, or fluctuance suggesting infection.
- Progressive enlargement or recurrence after initial settling.
- Firm, fixed swelling consistent with a granulomatous reaction.
- Any associated skin discolouration or signs of vascular compromise.
Evaluating Training in Biostimulator Techniques
For clinicians considering formal training, the value lies less in a product demonstration than in structured teaching of assessment, anatomy, reconstitution, plane selection, and complication management. A well-designed course should treat biostimulators as distinct from hyaluronic acid throughout, emphasising that irreversibility raises the threshold for careful case selection and conservative technique rather than lowering it.
It is worth being clear about what any short course can provide. A certificate of attendance or completion attests that a clinician participated and engaged with the material; it does not confer independent competence, specialist status, or a licence to practise a technique unsupervised. Competence develops through supervised practice, case volume, and reflective learning that extend well beyond a taught programme.
Within the UK, non-surgical cosmetic practice sits alongside professional standards from bodies such as the GMC and the JCCP, and training should reinforce rather than sidestep them. ATDERA develops faculty-led educational programmes for practising clinicians in this spirit. When appraising any programme, clinicians should ask how it teaches recognition and management of adverse events, not only injection itself.